By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


DiscoveRx Corporation 

42501 Albrae Street

Fremont  California  94538  U.S.A.
Phone: 510-979-1415 Fax: 510-979-1650


DiscoveRx® is a fast growing innovative company that develops, manufactures, and commercializes reagents and complete assay kits for the drug discovery and screening markets. Our products, biochemical and cell-based assays, enable customers to improve research productivity and effectiveness, thus accelerating the discovery and development of new drugs.

Founded in 2000, DiscoveRx is a privately held, venture-backed company headquartered in California with offices in England, Germany, and France. DiscoveRx is dedicated to the development and commercialization of innovative solutions to study major drug target classes such as GPCRs and kinases.

DiscoveRx assay solutions are based on our core proprietary Enzyme Fragment Complementation (EFC) technology that is well established in clinical diagnostics and now further enhanced to provide unique solutions to drug discovery research. EFC technology is a proven, established screening technology in most major pharmaceutical companies and our EFC-based HitHunter™ cAMP assays are the market leader in GPCR screening applications. PathHunter™ technology, an adaptation of EFC technology, is an innovative and comprehensive assay system that enables in vivo cell-based assays for pathway profiling and screening. Through our core HitHunter™, PathHunter™, and EFC technologies, DiscoveRx is able to offer assay solutions for every major class of drug target, including GPCRs, kinases, proteases, nuclear hormone receptors, transcription factors, and secreted proteins.

DiscoveRx – Simple Solutions for Complex Biology

Last Updated: 03-14-2006

Key Statistics

Ownership: Private

Web Site: DiscoveRx Corporation


Company News
DiscoveRx Corporation Release: Rapidly Screen Molecules For Novel Immuno-Oncology Therapeutics With Checkpoint Receptor Screening And Profiling Services 2/27/2017 7:58:13 AM
DiscoveRx Corporation Launches Services For Early Identification of Potential Drug Side Effects 9/19/2016 10:59:49 AM
DiscoveRx Corporation Launches Cell-Based Assays For Confirmation Of Compound-Target Engagement In Drug Discovery 9/19/2016 9:37:37 AM
DiscoveRx Corporation Launches KILR Assay Platform For Use In Cancer Immunotherapy Drug Development 3/29/2016 8:15:28 AM
Easily Measure Cancer Cell Death In A Co-Culture With KILR Assays From DiscoveRx Corporation 2/1/2016 7:32:19 AM
Rapidly Develop Drugs Targeting Interleukins With New PathHunter Cell-Based Assays From DiscoveRx Corporation 1/5/2016 7:39:52 AM
DiscoveRx Corporation Announces Extension Of Agreement With Blueprint Medicines (BPMC) 12/8/2015 9:16:38 AM
DiscoveRx Corporation Enables Predictive In Vitro Drug Combination Studies With Launch Of Biomap® Combo ELECT 5/21/2014 10:05:45 AM
DiscoveRx Corporation Platforms For Phenotypic And Target Based Screening Provide Unique Tools For Cancer Therapeutic Discovery 4/7/2014 10:51:46 AM
DiscoveRx Corporation And Collaborators Present Data On Safety, Bioactivities Of Wide Range Of Substances To Society Of Toxicology 3/27/2014 10:38:39 AM